Wolters Kluwer opens lobby shop in Washington

Share this article:

Wolters Kluwer Health has appointed its first VP-government affairs as the publishing giant seeks to head off state restrictions on commercial use of prescription data.

The company named longtime healthcare lobbyist Cathy Betz to the position. Betz has been a partner in her husband's Washington, DC, health policy consulting firm, Robert Betz Associates, for a quarter-century.

Wolters Kluwer's Healthcare Analytics unit, part of its Pharma Solutions business, offers prescribing pattern data. Last year, 23 states introduced legislation to restrict the sale or use of such data. In addition, Congress has been showing increasing interest of late in the potential influence of pharmaceutical firms on medical journals and CME. In August, the company joined IMS Health and Verispan in lawsuits aimed at blocking Maine and Vermont from implementing laws, slated to take effect in 2008, that would curb the collection and disclosure of physician prescribing information.

In addition to prescriber data access, “We're focusing on any e-health initiatives and this whole transparency issue in general on the state and federal level,” said Betz. “That's what's interesting about these [state] initiatives – they're really going against the trend towards transparency and I think that's why they'll fail. At the federal level, they understand that, and they're moving towards more access to more data, more information and more transparency as a way to improve health outcomes.”

Share this article:
You must be a registered member of MMM to post a comment.


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...